Related Experiment Videos
[Pain therapy with rhenium-186 HEDP in multiple bone metastases]
H Palmedo1, H Bender, A Schomburg
1Aus der Klinik für Nuklearmedizin, Universität Bonn, Deutschland.
Aim:
Therapeutic means for patients with painful bony metastases are strongly limited. In these patients, a systemic therapy with isotopes can be helpful. The aim of this study was to evaluate the efficacy of rhenium-186 HEDP for pain palliation in patients with disseminated bone metastases.
Methods:
30 patients taking analgesics because of bone pain received one or more injection of 1295 MBq 186Re HEDP for pain palliation.
Results:
In 70% of the patients, therapy resulted in a significant reduction of pain. The average duration of pain relief was 4 weeks (1 week-2.5 months). The main side effects of therapy were a decrease of platelets (aver. 30000/microliters) and an increase of pain for 1-2 days (flare-phenomenon).
Conclusion:
Therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy in patients with painful, disseminated bone metastases.